Formycon Strengthens Biosimilars Portfolio With Athos Assets

Deal Will Be Paid For With A Consideration Worth Approximately €650m

 
• By Chloe Kent
  
Formycon company logo icon on website
After the deal is closed Athos will be the largest shareholder in Formycon • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business